Loading...

KALV KALVISTA PHARMACEUTICALS INC Product Launches 8-K Filing

KLVS

KLV

KALVISTA PHARMACEUTICALS INC

(KALV)

2024 8-K

Show Summary

Show Summary

License Agreement

Fiscal Year Change

Financial Results

Management Change

Financial Results

Board Appointment

Revenue Rights Sale

Annual Meeting Results

Management Changes

Financial Results

Lease Agreement

Financial Results

Financial Results

Public Offering

Termination of Sales Agreement

Clinical Data Announcement

Financial Results

Amendment to Certificate of...

Financial Results

Amended Employment Agreement

Financial Results

Appointment of President

External Links:

KalVista Pharmaceuticals announced positive clinical data from its Phase 3 KONFIDENT trial for sebetralstat, demonstrating efficacy and safety in treating Hereditary Angioedema attacks.

AI Assistant

KALVISTA PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.